Disclaimer

Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

By clicking “Accept” you acknowledge and agree that neither ITGR nor third party provider Virtua Research, Inc. (“Virtua) is responsible, or accepts or assumes any responsibility or liability whatsoever for, the content, the data or the technical operation of the Linked Site. Further, by entering the External Site, you also acknowledge and agree that you completely and irrevocably waive any and all rights and claims against ITGR and Virtua and further acknowledge and agree that in no event shall ITGR or Virtua, its officers, employees, directors and agents be liable for any (i) indirect, consequential, incidental, special, compensatory or punitive damages, (ii) damages for loss of income, loss of business profits, business interruption, loss of data or business information, loss of or damage to property, (iii) claims of third parties, or (iv) other pecuniary loss, arising out of or related to this disclaimer or the External Site

By entering the External Site, you further acknowledge and agree that the disclaimer of warranties and limitations of liability set out in this disclaimer shall apply regardless of the causes, circumstances or form of action giving rise to the loss, damage, claim or liability, even if such loss, damage, claim or liability is based upon breach of contract (including, without limitation, a claim of fundamental breach or breach of a fundamental term), tort (including, without limitation, negligence), strict liability or any other legal or equitable theory, and even if ITGR and Virtua are advised of the possibility of the loss, damage, claim or liability. The waiver and release specifically includes, without limitation, any and all rights and claims pertaining to the processing of personal data, including but not limited to any rights under any applicable data protection statute(s).

If in any jurisdiction, any part of this disclaimer is held to be unenforceable by a court of competent jurisdiction, such part of this disclaimer shall be restricted or eliminated to the minimum extent and the remaining disclaimer shall otherwise remain in full force and effect.

Please note the information presented is deemed representative at the time of its original release. Changes in historical information may occur due to adjustments in accounting and reporting standards & procedures.

Non-GAAP Information

In addition to disclosing results determined in accordance with GAAP, ITGR may also disclose certain non-GAAP and pro forma non-GAAP results of operations, including certain ratios, operational and miscellaneous data, as well as net income, diluted earnings per share, operating expenses, and operating income that make certain adjustments or exclude certain charges and gains that are outlined in the schedules included in this website. Management believes that this non-GAAP and pro forma non-GAAP information provides investors with additional information to assess ITGR operating performance by making certain adjustments or excluding costs or gains and assists investors in comparing our operating performance to prior periods. Management uses this non-GAAP and pro forma non-GAAP information, along with GAAP information, in evaluating its historical operating performance. ITGR and Virtua also take no responsibility for third party pricing data provided for informational purposes and certain ratio results formulated from the provided third party pricing data.

The non-GAAP information is not prepared in accordance with GAAP and may not be comparable to non-GAAP information used by other companies. The non-GAAP information should not be viewed as a substitute for, or superior to, other data prepared in accordance with GAAP.

Integer Supports Respicardia’s Commercialization in the Central Sleep Apnea Market through Two New Agreements

January 14, 2019

PLANO, Texas and MINNETONKA, Minn., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Integer, a leading medical device outsource (MDO) manufacturer, today announced it has entered into a new development agreement and a new supply agreement with Respicardia, Inc., a medical technology company dedicated to developing innovative therapies that address unmet needs in respiratory and cardiovascular disease. Under the agreements, Integer will be Respicardia’s development partner and majority supplier of the remedē® implantable pulse generator (IPG) and related products for seven years, the first 5 ½ years as an exclusive supplier.

“We’re honored to continue supporting Respicardia in bringing their therapy to market,” said Tony Gonzalez, president of Integer’s Cardiac Rhythm Management and Neuromodulation product line. “We supported their initial system development as they worked through their clinical studies, so it’s exciting to see their transition to commercialization. These agreements highlight Integer’s breadth of capabilities to support customers with design, development and manufacturing of custom IPG systems. Our end-to-end expertise will help Respicardia ensure the utmost quality and reliability of their products.”

“In product innovation, quality, and uncompromising clinical performance, Integer-manufactured devices are second-to-none,” said Peter Sommerness, President and CEO of Respicardia. “Integer is recognized as an innovative company that shares our vision to improve patient quality of life and overall health. Respicardia sought a partner with the ability to scale the production to meet the market needs of our unique therapies.”

Respicardia’s remedē® System is a transvenous neurostimulation device that treats moderate to severe central sleep apnea in adult patients. Central Sleep Apnea (CSA) is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health. CSA results from the brain’s failure to send appropriate signals to the respiratory muscles to stimulate breathing.

About Integer

Integer (NYSE: ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical, advanced surgical and orthopedics markets. The company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company's brands include Greatbatch™ Medical, Lake Region Medical™ and Electrochem. Additional information is available at www.integer.net.

About Respicardia

Respicardia is a leader in innovative technologies that address the unmet needs in respiratory and cardiovascular disease with safe and effective therapies. Founded in 2006 and headquartered near Minneapolis, Minn., Respicardia is dedicated to improving patient outcomes, quality of life and overall cardiovascular health via novel transvenous neurostimulation therapies. Learn more at www.respicardia.com.

Contacts

Integer Investor Relations
Tony Borowicz
tony.borowicz@integer.net
716.759.5809

Integer Media Relations
Kelly Butler
kelly.butler@integer.net
214.618.4216

Respicardia Media Relations
Collin Anderson
canderson@respicardia.com
952.540.4474

integer logo.jpg

Source: Integer Holdings Corporation